This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema

This study has been withdrawn prior to enrollment.
(PI left institution (there are no data results for this study))
Information provided by:
Icahn School of Medicine at Mount Sinai Identifier:
First received: August 11, 2009
Last updated: June 21, 2011
Last verified: June 2011
The purpose of this study is to determine if intravitreal infliximab is a safe and effective treatment for macular edema secondary to uveitis.

Condition Intervention Phase
Uveitic Macular Edema Intraocular Inflammation Drug: Infliximab (intravitreal, 2.0mg/0.05ml) Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema

Resource links provided by NLM:

Further study details as provided by Icahn School of Medicine at Mount Sinai:

Primary Outcome Measures:
  • Best-corrected visual acuity [ Time Frame: Three months ]

Secondary Outcome Measures:
  • Macular thickness [ Time Frame: One, two, and three months ]

Estimated Enrollment: 10
Study Start Date: August 2009
Study Completion Date: October 2009
Arms Assigned Interventions
Experimental: Intravitreal infliximab Drug: Infliximab (intravitreal, 2.0mg/0.05ml)
One injection of intravitreal infliximab (2.0mg/0.05ml).
Other Name: Remicade™

Detailed Description:
Participants with uveitic macular edema will be treated with one injection of intravitreal infliximab (2.0mg/0.05ml) and followed for three months. Outcomes that be assessed include best-corrected visual acuity, macular thickness as measured by optical coherence tomography, and electroretinogram responses.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Participant must be 18 years of age or older.
  2. Participant must understand and sign the protocol's informed consent document.
  3. Participants must have uveitic macular edema in one eye as defined by all of the following criteria:

    1. Presence of active intermediate uveitis or posterior uveitis.
    2. Macular edema defined as a central macular thickness of ≥ 250 μm on OCT.
    3. Uveitis must be noninfectious as determined by standard investigations used in the diagnostic investigation of uveitis.
  4. Participant must have visual acuity between 20/40 and hand motions in the study eye.
  5. Participant must have a steady fixation in the study eye and media clear enough for good quality imaging.
  6. Female participants of childbearing potential must not be pregnant or breast-feeding, must have a negative pregnancy test at screening and must practice an adequate method of birth control. Males able to father a child must agree to practice birth control. Acceptable methods of birth control include hormonal contraception (birth control pills, injected hormones or vaginal ring), intrauterine device, barrier methods with spermicide (diaphragm with spermicide, condom and spermicide) or surgical sterilization (hysterectomy, tubal ligation or vasectomy in a partner). If a participant is of childbearing potential, she must be willing to undergo monthly urine pregnancy tests. Both males and females must agree to use adequate birth control for three months after the intravitreal infliximab injection.

Exclusion Criteria:

  1. Participant is in another investigational study and actively receiving study therapy.
  2. Participant is unable to comply with study procedures or follow-up visits.
  3. Participant has uveitic macular edema (as defined above) in both eyes.
  4. Participant has multiple sclerosis or symptoms suggestive of multiple sclerosis.
  5. Participant has evidence of ocular disease other than uveitis in either eye that may confound the outcome of the study (e.g., diabetic retinopathy, age-related macular degeneration, vitreomacular traction, moderate/severe myopia, etc.).
  6. Participant is expected to need ocular surgery in the study eye during the course of the study.
  7. Participant has undergone ocular surgery or an intravitreal/periocular steroid injection in the study eye within the past 3 months.
  8. Participant has had a YAG laser capsulotomy or intravitreal anti-VEGF treatment in the study eye within the past 6 weeks.
  9. Participant has had a pars plana vitrectomy in the study eye.
  10. Participant is on ocular or systemic medications known to be toxic to the lens, retina, or optic nerve.
  11. Participant with a history of ocular herpes simplex virus infection in the study eye.
  12. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control).
  13. There are no criteria for inclusion/exclusion for the fellow eye. Only one eye can have macular edema in order for the potential participant to be considered for enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00958906

United States, New York
Department of Ophthalmology, Mount Sinai School of Medicine
New York, New York, United States, 10029
Sponsors and Collaborators
Icahn School of Medicine at Mount Sinai
Principal Investigator: Farzin Forooghian, MD Icahn School of Medicine at Mount Sinai
  More Information

Responsible Party: Farzin Forooghian, MD, Assistant Professor, Department of Ophthalmology, Mount Sinai School of Medicine Identifier: NCT00958906     History of Changes
Other Study ID Numbers: GCO # 09-0611
Study First Received: August 11, 2009
Last Updated: June 21, 2011

Keywords provided by Icahn School of Medicine at Mount Sinai:
Macular Edema
Intraocular Inflammation

Additional relevant MeSH terms:
Macular Edema
Pathologic Processes
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Uveal Diseases
Dermatologic Agents
Gastrointestinal Agents
Antirheumatic Agents processed this record on August 16, 2017